European Patent Ruling

Apr 05, 2001, 01:00 ET from Arriva Pharmaceuticals, Inc. and Baxter International Inc.

    ALAMEDA, Calif., April 5 /PRNewswire Interactive Release/ -- Arriva
 Pharmaceuticals, Inc. and Baxter International Inc. (NYSE:   BAX) today
 announced that Arriva's European patent on the use of alpha 1-antitrypsin and
 other protease inhibitors (European Patent No. 0 512 090) was upheld by the
 European Patent Office in amended form.  Oppositions to the patent had been
 filed by Bayer AG, Aventis, and Genzyme Transgenics Corporation.
     Martin Preuveneers, Ph.D., Arriva's Chairman and CEO, stated, "This ruling
 clearly establishes our proprietary rights, and gives additional impetus to
 our alpha 1-antitrypsin program in Europe."
     The ruling also allowed broad coverage for the use of additional protease
 inhibitors, such as the secretory leukocyte protease inhibitor (SLPI), for the
 treatment of asthma and skin diseases.
     Arriva Pharmaceuticals is a private company with a focus on the treatment
 of inflammatory disease using either inhaled or topically-applied protease
 inhibitors.  Its lead potential therapeutic is an alpha 1-antitrypsin (AAT)
 protein produced in genetically-engineered yeast cells.  The company's yeast
 manufacturing process utilizes no animal-sourced materials.  Arriva has
 developed a line of therapeutic protease inhibitors for the treatment of
 respiratory diseases such as hereditary emphysema, asthma, chronic obstructive
 pulmonary disease (COPD), and cystic fibrosis, and for the treatment of
 dermatological diseases such as atopic dermatitis and psoriasis.
     Baxter Healthcare Corporation is the principal U.S. subsidiary of Baxter
 International Inc. (NYSE:   BAX), a global medical products and services company
 that focuses on critical therapies for people with life-threatening
 conditions.  Baxter's medical products and services include blood therapies,
 medication delivery and renal therapy, and are used by healthcare providers
 and their patients in more than 100 countries.  The Hyland Immuno business of
 Baxter Healthcare Corporation develops and produces therapeutic proteins from
 plasma and through recombinant methods to treat hemophilia, immune
 deficiencies, and other blood-related disorders.  Hyland Immuno's portfolio of
 therapies includes coagulation factors, immune globulins, albumin, wound
 management products and vaccines.
 
     NOTE:  This news release contains forward-looking statements that involve
 risks and uncertainties, including risks associated with clinical development,
 regulatory approvals, product commercialization and other risks described from
 time to time in offering documents prepared by Arriva Pharmaceuticals, Inc.
 (formerly AlphaOne Pharmaceuticals).  An electronic version of this news
 release, as well as additional information about Arriva, of interest to
 investors, customers, future employees and patients is available on the Arriva
 Pharmaceuticals home page at http://www.arrivapharm.com.
 
     CONTACTS:
     Martin J. Preuveneers, Ph.D.        Lora Pike (media)
     Chairman and CEO                    Noonan/Russo Communications
     510-337-2846                        415-677-4455, ext. 211
 
                     MAKE YOUR OPINION COUNT -  Click Here
             http://tbutton.prnewswire.com/prns.jsp?11690X46855391
 
 

SOURCE Arriva Pharmaceuticals, Inc. and Baxter International Inc.
    ALAMEDA, Calif., April 5 /PRNewswire Interactive Release/ -- Arriva
 Pharmaceuticals, Inc. and Baxter International Inc. (NYSE:   BAX) today
 announced that Arriva's European patent on the use of alpha 1-antitrypsin and
 other protease inhibitors (European Patent No. 0 512 090) was upheld by the
 European Patent Office in amended form.  Oppositions to the patent had been
 filed by Bayer AG, Aventis, and Genzyme Transgenics Corporation.
     Martin Preuveneers, Ph.D., Arriva's Chairman and CEO, stated, "This ruling
 clearly establishes our proprietary rights, and gives additional impetus to
 our alpha 1-antitrypsin program in Europe."
     The ruling also allowed broad coverage for the use of additional protease
 inhibitors, such as the secretory leukocyte protease inhibitor (SLPI), for the
 treatment of asthma and skin diseases.
     Arriva Pharmaceuticals is a private company with a focus on the treatment
 of inflammatory disease using either inhaled or topically-applied protease
 inhibitors.  Its lead potential therapeutic is an alpha 1-antitrypsin (AAT)
 protein produced in genetically-engineered yeast cells.  The company's yeast
 manufacturing process utilizes no animal-sourced materials.  Arriva has
 developed a line of therapeutic protease inhibitors for the treatment of
 respiratory diseases such as hereditary emphysema, asthma, chronic obstructive
 pulmonary disease (COPD), and cystic fibrosis, and for the treatment of
 dermatological diseases such as atopic dermatitis and psoriasis.
     Baxter Healthcare Corporation is the principal U.S. subsidiary of Baxter
 International Inc. (NYSE:   BAX), a global medical products and services company
 that focuses on critical therapies for people with life-threatening
 conditions.  Baxter's medical products and services include blood therapies,
 medication delivery and renal therapy, and are used by healthcare providers
 and their patients in more than 100 countries.  The Hyland Immuno business of
 Baxter Healthcare Corporation develops and produces therapeutic proteins from
 plasma and through recombinant methods to treat hemophilia, immune
 deficiencies, and other blood-related disorders.  Hyland Immuno's portfolio of
 therapies includes coagulation factors, immune globulins, albumin, wound
 management products and vaccines.
 
     NOTE:  This news release contains forward-looking statements that involve
 risks and uncertainties, including risks associated with clinical development,
 regulatory approvals, product commercialization and other risks described from
 time to time in offering documents prepared by Arriva Pharmaceuticals, Inc.
 (formerly AlphaOne Pharmaceuticals).  An electronic version of this news
 release, as well as additional information about Arriva, of interest to
 investors, customers, future employees and patients is available on the Arriva
 Pharmaceuticals home page at http://www.arrivapharm.com.
 
     CONTACTS:
     Martin J. Preuveneers, Ph.D.        Lora Pike (media)
     Chairman and CEO                    Noonan/Russo Communications
     510-337-2846                        415-677-4455, ext. 211
 
                     MAKE YOUR OPINION COUNT -  Click Here
             http://tbutton.prnewswire.com/prns.jsp?11690X46855391
 
 SOURCE  Arriva Pharmaceuticals, Inc. and Baxter International Inc.